Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety

FDA is reviewing data from a large, long-term clinical study on possible risks for cardiovascular outcomes associated with use of rosiglitazone, known as Avandia.

Related Posts:

1. Benicar (olmesartan): Ongoing Safety Review
2. Senate Report Questions Avandia
3. Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review
4. Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures
5. Financial Interests Should Be Clearer To Increase Trust In Science Suggests Study Of Research Behind Anti Diabetes Drug